Albany Molecular Research (AMRI) Tops Q2 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/25/2026
- Wall St edges up on AI enthusiasm, Mideast negotiation hopes
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices drop about 3% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- Akamai signs $11.6B deal with Anthropic, up to $20B potential
- Bloom Energy falls as Oracle invokes force majeure on AI project
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oracle Sends Force Majeure Notice Over New Mexico Data Center - Bloomberg
- US and Iran discuss phased deal to reopen Hormuz and end US blockade, sources say
AMRI Announces Second Quarter 2015 Results
August 4, 2015 7:30 AM EDTALBANY, N.Y., Aug. 4, 2015 /PRNewswire/ --Â AMRI (NASDAQ: AMRI) today reported financial and operating results for the second quarter ended June 30, 2015.
Highlights:
Second quarter contract revenue of $85.2 million, a 39% increase from 2014 Adjusted contract margins of 26% Second quarter adjusted diluted EPS of $0.22, including a $0.05 decrease in EPS from royalties in the current quarter Operating cash flow of $16 million"We are very pleased to present another strong financial quarter, with all our divisions achieving excellent... More
